EBMT 2022 | Update on the CART19-BE-02 trial
Valentín Ortiz-Maldonado, MD, Hospital Clínic de Barcelona, Barcelona, Spain, explains the design and objectives of the Phase II CART19-BE-02 dose-escalation trial (NCT04778579) evaluating the safety and efficacy of the chimeric antigen receptor T-cell (CAR-T) therapy ARI-0001 from 1M to 3M cells/kg in 32 patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Previous work with 1M cells/Kg showed 85% complete remission, so the main objective focused on increasing the proportion of long-term responders after one and five years. The study is recruiting, and the first results are expected for 2023. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Research grants: Fundación Española de Hematología y Hemoterapia
Travel grants: Kite, Celgene, Novartis, Roche, Takeda & Janssen
Consultant or advisory fees: Kite, Celgene-BMS, Novartis & Janssen
Honoraria: Kite
Employment: Hospital Clínic, Barcelona
